Breast Cancer Trial, Recruiting (NCT06833853)

Breast Cancer Trial, Recruiting NCT06833853 Sponsor: Menarini Silicon Biosystems, INC Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06833853 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with invasive breast cancer that has spread to other parts of the body or cannot be removed with surgery.
People whose breast cancer is hormone receptor positive and HER2 negative, or triple negative, and who are about to start or have already started treatment for advanced/spread disease.
People whose breast cancer is HER2 positive and who are about to start or have already started their second or later round of treatment for advanced/spread disease.
People who have had specific blood and biomarker tests (including CTC HER2, ER, PD-L1, and cfDNA/RNA tests) ordered as part of their regular cancer care.
People who are over 18 years of age.

Who may not be able to join:

People who are currently pregnant.
People who are unable to provide blood samples, based on their treating doctor's assessment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marija Balic, MD, PhD, MBA, University of Pittsburgh

Phone: 800-533-8762

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06833853

Sponsor: Menarini Silicon Biosystems, INC

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: 800-533-8762

More information: https://clinicaltrials.gov/study/NCT06833853

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with invasive breast cancer that has spread to other parts of the body or cannot be removed with surgery.
People whose breast cancer is hormone receptor positive and HER2 negative, or triple negative, and who are about to start or have already started treatment for advanced/spread disease.
People whose breast cancer is HER2 positive and who are about to start or have already started their second or later round of treatment for advanced/spread disease.
People who have had specific blood and biomarker tests (including CTC HER2, ER, PD-L1, and cfDNA/RNA tests) ordered as part of their regular cancer care.
People who are over 18 years of age.

Who may not be able to join:

People who are currently pregnant.
People who are unable to provide blood samples, based on their treating doctor's assessment.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Menarini Silicon Biosystems, INC

Registry

ClinicalTrials.gov

Start date

13 March 2026

Est. completion

1 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The percentage of subjects for which the providers indicated positive impact of the cfDNA/RNA, CTC enumeration, and CTC expression results.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov